Irinotecan vs non‐irinotecan‐containing regimens
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Irinotecan showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐irinotecan‐containing regimens (moderate certainty).
1 finding from 1 review
- HR 0.87 [0.75, 1]6 studies · 826 participantsModerate